SG Americas Securities LLC Has $658,000 Stock Position in Denali Therapeutics Inc. (NASDAQ:DNLI)

SG Americas Securities LLC increased its position in shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 339.6% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 48,365 shares of the company's stock after acquiring an additional 37,362 shares during the period. SG Americas Securities LLC's holdings in Denali Therapeutics were worth $658,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently added to or reduced their stakes in DNLI. Norges Bank acquired a new stake in Denali Therapeutics in the fourth quarter valued at approximately $21,717,000. Vanguard Group Inc. boosted its position in Denali Therapeutics by 7.6% in the fourth quarter. Vanguard Group Inc. now owns 12,021,230 shares of the company's stock valued at $244,993,000 after buying an additional 843,996 shares in the last quarter. Polar Asset Management Partners Inc. boosted its position in Denali Therapeutics by 1,240.9% in the fourth quarter. Polar Asset Management Partners Inc. now owns 551,092 shares of the company's stock valued at $11,231,000 after buying an additional 509,992 shares in the last quarter. Balyasny Asset Management L.P. raised its stake in shares of Denali Therapeutics by 822.4% during the fourth quarter. Balyasny Asset Management L.P. now owns 416,074 shares of the company's stock valued at $8,480,000 after acquiring an additional 370,966 shares during the last quarter. Finally, Millennium Management LLC raised its stake in shares of Denali Therapeutics by 571.8% during the fourth quarter. Millennium Management LLC now owns 404,224 shares of the company's stock valued at $8,238,000 after acquiring an additional 344,056 shares during the last quarter. Institutional investors and hedge funds own 92.92% of the company's stock.

Denali Therapeutics Stock Down 1.4%

DNLI traded down $0.20 during midday trading on Friday, hitting $13.89. The company had a trading volume of 1,528,824 shares, compared to its average volume of 1,119,174. Denali Therapeutics Inc. has a 52 week low of $10.57 and a 52 week high of $33.33. The company has a market capitalization of $2.02 billion, a price-to-earnings ratio of -5.20 and a beta of 1.33. The stock's 50 day moving average price is $14.32 and its 200 day moving average price is $17.39.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The company reported ($0.78) earnings per share for the quarter, missing the consensus estimate of ($0.71) by ($0.07). During the same quarter in the previous year, the company earned ($0.68) EPS. Research analysts predict that Denali Therapeutics Inc. will post -2.71 EPS for the current year.

Analysts Set New Price Targets

Several research firms have recently issued reports on DNLI. Robert W. Baird dropped their price target on shares of Denali Therapeutics from $30.00 to $29.00 and set an "outperform" rating for the company in a research note on Thursday, May 8th. Cantor Fitzgerald raised shares of Denali Therapeutics from a "neutral" rating to an "overweight" rating in a research note on Thursday, April 10th. HC Wainwright dropped their price target on shares of Denali Therapeutics from $80.00 to $32.00 and set a "buy" rating for the company in a research note on Wednesday, May 7th. Oppenheimer dropped their price target on shares of Denali Therapeutics from $50.00 to $42.00 and set an "outperform" rating for the company in a research note on Monday, March 3rd. Finally, Morgan Stanley began coverage on shares of Denali Therapeutics in a research note on Friday, March 7th. They set an "overweight" rating and a $33.00 price target for the company. One analyst has rated the stock with a hold rating, fourteen have given a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of "Buy" and a consensus target price of $33.71.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.